APE1 Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF20.00 |
| 52 Week High | CHF25.00 |
| 52 Week Low | CHF5.45 |
| Beta | 1.76 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -87.34% |
| 5 Year Change | n/a |
| Change since IPO | -91.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| APE1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | -1.2% |
| 1Y | n/a | -19.8% | 1.8% |
Return vs Industry: Insufficient data to determine how APE1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how APE1 performed against the German Market.
Price Volatility
| APE1 volatility | |
|---|---|
| APE1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: APE1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine APE1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
| APE1 fundamental statistics | |
|---|---|
| Market cap | €7.97m |
| Earnings (TTM) | -€10.75m |
| Revenue (TTM) | €1.68m |
4.8x
P/S Ratio-0.7x
P/E RatioIs APE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APE1 income statement (TTM) | |
|---|---|
| Revenue | CHF1.65m |
| Cost of Revenue | CHF6.94m |
| Gross Profit | -CHF5.29m |
| Other Expenses | CHF5.27m |
| Earnings | -CHF10.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -0.082 |
| Gross Margin | -321.08% |
| Net Profit Margin | -640.91% |
| Debt/Equity Ratio | 0% |
How did APE1 perform over the long term?
See historical performance and comparison